false
0001358403
0001358403
2024-01-30
2024-01-30
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): January 30, 2024
Bellicum Pharmaceuticals, Inc.
(Exact name of registrant as specified
in its charter)
| Delaware |
|
001-36783 |
|
20-1450200 |
(State
or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification No.) |
3730 Kirby Drive, Ste. 1200, Houston,
TX 77098
(Address of principal executive offices,
including zip code)
Registrant’s telephone number,
including area code: 281-454-3424
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section
12(b) of the Act: None.
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
As previously disclosed in the Current Report on Form 8-K filed on January 24, 2024 by Bellicum Pharmaceuticals, Inc., a Delaware corporation (the “Company”), on January 24, 2024, the Company convened a special meeting of stockholders, which was subsequently adjourned (the “Special Meeting”), for the purpose of approving (i) the Asset Purchase Agreement, dated November 21, 2023 (such agreement,
as amended on December 8, 2023 pursuant to that certain Amendment No. 1 to Asset Purchase Agreement and as it may be further amended, modified or supplemented from time to time, the “Asset Purchase Agreement”), by and among the Company and The University of Texas M. D. Anderson Cancer Center, an institution of higher education and an agency of the State of Texas (“MDACC”), which provides for the sale to MDACC of certain assets, including all rights to each program of research
and development related to (a) CaspaCIDe (inducible caspase-9), the Rimiducid-inducible safety switch designed to abrogate high-grade adverse events associated with genetically-modified cell therapies, (b) inducible MyD88/CD40 (iMC), the Rimiducid-inducible activation switch designed to enhance effector cell proliferation and persistence and to resist exhaustion and inhibitory signals, (c) dual-switch GoCAR-T, incorporating both iMC and a modified rapalog-inducible caspase-9 safety
switch, and (d) Rimiducid (the “Asset Sale”), and may be deemed under Delaware law to be a sale of substantially all of our assets, and the consummation of the other transactions contemplated by the Asset Purchase Agreement (the “Asset Sale Proposal”) and (ii) subject to approval of the Asset Sale Proposal, the liquidation and dissolution of the Company in accordance with Section 275 of the Delaware General Corporation Law (the “Dissolution”) and pursuant to the
Plan of Dissolution attached to the Information Statement (as defined herein) (the “Plan of Dissolution”) (the “Dissolution Proposal”). There were 4,132,740 shares of common stock of the Company present or represented by proxy at the Special Meeting, which did not constitute a quorum under the Company bylaws.
Accordingly, the Special Meeting was adjourned without any business being conducted in order to allow time to achieve a quorum and to allow the Company’s stockholders additional time to vote on the Asset Sale Proposal and Dissolution Proposal.
The Special Meeting is scheduled to reconvene virtually on Wednesday, February 20, 2024, at 8 a.m., Pacific Time (the “Reconvened Special Meeting”) for Company stockholders to vote on the Asset Sale Proposal and Dissolution Proposal. The close of business on January 29, 2024, is the new record date for the determination of stockholders of the Company entitled to vote at the Reconvened Special Meeting. Record
stockholders of the Company who have previously submitted their proxy or otherwise voted do not need to take any action. Stockholders who hold their shares in “street name” and submitted a voting instruction form for the Special Meeting are encouraged to reach out to their bank, broker or other nominee to determine whether they are required to submit another voting instruction form in order to vote at the Reconvened Special Meeting. No changes have been made in the proposals to be voted
on by stockholders at the Reconvened Special Meeting.
During the adjournment period, the Company will continue to solicit votes from its stockholders with respect to the Asset Sale Proposal and the Dissolution Proposal. The Company encourages all stockholders who have not yet voted to do so promptly. As of January 29, 2024, the Company had 11,833,280 shares of common stock issued and outstanding.
A copy of the notice of the reconvened special meeting of stockholders is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
The Company encourages all of its stockholders to read the Company’s information statement relating to the Special Meeting (the “Information Statement”) furnished with the Current Report on Form 8-K filed on December 14, 2023, by the Company, which is available free of charge on the SEC website at www.sec.gov.
Cautionary Note Regarding Forward-Looking Statements
This Current Report on Form 8-K contains “forward-looking statements” which include, but are not limited to, all statements that do not relate solely to historical or current facts, such as statements regarding the Company’s expectations, intentions or strategies regarding the future, the timing and outcome of the Reconvened Special Meeting, and the completion or effects of the Asset Sale and the
Dissolution. In some cases, these statements include words like: “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue” and “ongoing,” or the negative of these terms,
or
other comparable terminology intended to identify statements about the future. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a
result of uncertainties, risks, and changes in circumstances, including but not limited to risks and uncertainties related to: the Company obtaining the requisite stockholder vote to approve the Asset Sale and the Dissolution, the ability of the parties to consummate the Asset Sale, satisfaction of closing conditions precedent to the consummation of the Asset Sale, potential delays in consummating the Asset Sale, the ability of the Company to timely execute the Dissolution, the execution costs to
the Company of the Asset Sale and the Dissolution, the extent of other liabilities that the Company will be required to satisfy or reserve for in connection with the Dissolution, the impact of these costs and other liabilities on the cash, property and other assets available for distribution to the stockholders in the Dissolution, and the amount of cash (if any) that will be distributed to the stockholders in connection with the Asset Sale and the Dissolution. Additional risks and uncertainties that
could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption “Risk Factors” and elsewhere in the Company’s most recent filings with the SEC, including the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 and any subsequent reports on Form 10-K, Form 10-Q or Form 8-K filed with the SEC from time to time and available at www.sec.gov. The forward-looking are
made only as of the date thereof, respectively. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
Bellicum
Pharmaceuticals, Inc. |
| |
|
|
|
Dated:
January 30, 2024 |
By: |
|
/s/
Richard A. Fair |
| |
|
|
Richard A. Fair |
| |
|
|
Principal Executive and Financial Officer |
Exhibit 99.1
Bellicum Pharmaceuticals,
Inc.
3730 Kirby Drive, Ste. 120
Houston, TX 77098
(281) 454-3424
NOTICE OF SPECIAL MEETING OF STOCKHOLDERS
TO BE RECONVENED ON FEBRUARY 20, 2024
Notice is hereby given that
the special meeting of stockholders of Bellicum Pharmaceuticals, Inc., a Delaware corporation (“Bellicum,” “we,”
“us” or “our”), originally convened and adjourned on January 24, 2024, will be reconvened
virtually on February 20, 2024, at 8:00 a.m. Pacific Time via live audio webcast on the Internet at https://www.viewproxy.com/BLCM/2024/,
for the following purposes:
1. To
adopt and approve the Asset Purchase Agreement, dated November 21, 2023 (such agreement, as amended on December 8, 2023 pursuant to that
certain Amendment No. 1 to Asset Purchase Agreement and as it may be further amended, modified or supplemented from time to time, the
“Asset Purchase Agreement”), by and among Bellicum and The University of Texas M. D. Anderson Cancer Center,
an institution of higher education and an agency of the State of Texas (“MDACC”), providing for the sale to
MDACC of certain assets, including all rights to each program of research and development related to (a) CaspaCIDe (inducible caspase-9),
the Rimiducid-inducible safety switch designed to abrogate high-grade adverse events associated with genetically-modified cell therapies,
(b) inducible MyD88/CD40 (iMC), the Rimiducid-inducible activation switch designed to enhance effector cell proliferation and persistence
and to resist exhaustion and inhibitory signals, (c) dual-switch GoCAR-T, incorporating both iMC and a modified rapalog-inducible caspase-9
safety switch, and (d) Rimiducid (the “Asset Sale”), which may be deemed under Delaware law to be a sale of
substantially all of our assets, and the consummation of the other transactions contemplated by the Asset Purchase Agreement (the “Asset
Sale Proposal”).
2. To
approve, subject to approval of Asset Sale Proposal, the liquidation and dissolution of Bellicum in accordance with Section 275 of the
Delaware General Corporation Law (the “Dissolution”) and pursuant to the Plan of Dissolution which, if approved,
will authorize Bellicum to liquidate and dissolve in accordance with the Plan of Dissolution (the “Dissolution Proposal”).
Stockholders will need the control
number on your proxy card to attend, vote and otherwise participate at the reconvened special meeting. If you are a beneficial owner who
does not have a control number, you should contact your broker, bank or other nominee regarding instructions to attend the reconvened
special meeting.
We previously provided the Information
Statement of Bellicum Pharmaceuticals, Inc. dated December 14, 2023 (the “information statement”) to our stockholders
of record as of December 13, 2023, which provided detailed information about the originally convened special meeting, the Asset Purchase
Agreement, the Amendment to Asset Purchase Agreement and the Asset Sale, and the Plan of Dissolution and the Dissolution. Copies of the
Asset Purchase Agreement, the Amendment to Asset Purchase Agreement and the Plan of Dissolution are attached as Annex A-1, Annex A-2 and
Annex B, respectively, to such information statement, which can be accessed at the following web address: https://www.sec.gov/Archives/edgar/data/1358403/000153949723002188/exh99-1.htm.
Such information statement and the attachments thereto are incorporated herein by reference, other than any information therein relating
to (i) the quorum requirements for, (ii) the record date and date and time of, (iii) the means of remote communication to access, and
(iv) and the granting and revocation of proxies with respect to, the reconvened special meeting, which are addressed by this notice. We
urge you to read such information statement and attachments carefully. If you need assistance accessing the information statement, including
its annexes, please contact Alliance Advisors LLC at (844) 984-3716, which is a dedicated line for Bellicum’s stockholders.
The presence, in person or by
proxy, of the holders of a majority of the voting power of the outstanding shares of our capital stock entitled to vote at the reconvened
special meeting constitutes a quorum for the transaction of business thereat and the approval of each of the Asset Sale Proposal and the
Dissolution Proposal requires the affirmative vote of the holders of a majority of the voting power of our outstanding capital stock entitled
to vote thereon. At the
originally convened session
of the special meeting, although the proxies we received and voting “for” each of the Asset Sale Proposal and the Dissolution
Proposal exceeded the proxies we received and voting “against” or “abstaining” with respect to each such proposal,
we did not receive valid proxies (i) from the requisite number of stockholders to establish a quorum at the special meeting and (ii) authorizing
the proxyholders to, in the aggregate, vote a majority of the voting power of the outstanding shares of our capital stock entitled to
vote thereon in favor of each of the Asset Sale Proposal and the Dissolution Proposal. Therefore, as contemplated by the information statement,
we adjourned the special meeting and our Board of Directors authorized and issued the Super-Voting Share (as defined in the information
statement), which is designated as Series A Junior Preferred Stock, to Richard A. Fair. The Super-Voting Share entitles the holder thereof
to cast on each matter submitted for stockholder approval at the special meeting a number of votes equal to the number of shares of Common
Stock outstanding on the record date, provided that the holder casts such votes in manner that is proportionate to the manner in which
all shares of Common Stock present, in person or by proxy, at the special meeting are voted with respect to such matter, such that, the
votes cast by the Super-Voting Share shall reflect the voting results with respect to “shares voted for,” “shared voted
against,” and “shares abstained” (if any) proportionate to such aggregate voting results of the Common Stock present,
in person or by proxy, on such matter. The Board thereafter set a new record date for the reconvened meeting. Only stockholders of record
as of the close of business on January 29, 2024, are entitled to notice of and to vote at the reconvened special meeting (the “new
record date”).
As of the close of business
on the new record date there were 11,901,026 shares of Common Stock outstanding and one share of Series A Junior Preferred Stock outstanding
(which generally entitles the holder thereof to cast 11,901,026 votes), meaning that the holders of outstanding stock entitling such holders
to cast, in the aggregate, 11,901,027 votes at the special meeting must be present, in person or by proxy, at such meeting to establish
a quorum.
Bellicum’s Board of
Directors continues unanimously to recommend, on behalf of Bellicum, that you vote: (1) “FOR” the approval of the Asset Sale
Proposal; and (2) “FOR” the approval of the Dissolution Proposal.
Your vote is important regardless
of the number of shares of Bellicum’s capital stock that you own. Although the issuance of the Super-Voting Share will likely result
in a majority of the outstanding voting power of Bellicum’s capital stock being cast on each proposal, because such stock must be
voted in proportion to the Common Stock (as described above), in order for such proposals to be approved, the holders of a majority of
the outstanding shares of Common Stock present, in person or by proxy, at the reconvened special meeting must vote “FOR” such
proposals. Accordingly, you are requested to vote your shares of Bellicum capital stock by proxy promptly by either (a) using the toll-free
number as described in the proxy card attached hereto as Annex
A, (b) using the Internet as described in the enclosed proxy card or (c) by completing, signing, and promptly mailing the proxy
card in the postage-paid envelope provided, whether or not you plan to attend the special meeting. Voting in any of these ways will not
prevent you from voting your shares at the reconvened special meeting if you subsequently choose to attend.
If you previously submitted
a proxy for the special meeting of stockholders as originally convened on January 24, 2024, which proxy has not subsequently been revoked,
and are a holder of record on the new record date, we intend to vote those proxies, covering all shares of our capital stock that you
are entitled to vote as of the new record date, at the reconvened special meeting as specifically instructed through your proxy or, if
no direction was given, “FOR” each of the Asset Sale Proposal and the Dissolution Proposal. If you are a stockholder of record
as of the new record date, you may change your vote or revoke your proxy at any time before it is voted at the special meeting by (i)
signing another proxy card with a later date and returning it to us prior to the special meeting; (ii) submitting a new proxy electronically
over the Internet or by telephone after the date of the earlier submitted proxy; (iii) delivering a written notice of revocation to Bellicum
Pharmaceuticals, Inc., Attn: Corporate Secretary, 3730 Kirby Drive, Suite 1200, Houston, TX 77098, by 11:59 p.m. Pacific Time on February
19, 2024; or (iv) attending the special meeting and voting thereat.
If you are a stockholder of
record on the new record date, in order to attend the reconvened special meeting, you must register at https://www.viewproxy.com/BLCM/2024/
by 11:59 ET on February 18, 2024. On the day of the reconvened special meeting, if you have properly registered, you may enter the meeting
by clicking on the link provided and the password you receive via email in your registration confirmation. If you previously so registered
for the originally convened special meeting you must register again for the reconvened special meeting.”
If you hold your shares in “street
name,” you should instruct your bank, broker or other nominee how to vote your shares in accordance with the voting instruction
form that you will receive from your bank, broker or other nominee. We intend to ask your bank, broker or other nominee to vote your shares
in accordance with any previously-delivered voting instruction form, but we cannot guarantee that your bank, broker or other nominee will
vote your shares with respect to any of the proposals if you do not submit a new voting instruction form for the reconvened meeting. You
should contact your bank, broker or other nominee to determine whether your bank, broker or other nominee will vote your shares at the
reconvened special meeting as previously directed with respect to the originally convened special meeting, for directions as to how to
change or revoke any prior voting instructions, and for any requirement to obtain a “legal proxy”, which is necessary for
a beneficial owner to vote at the reconvened special meeting. As an alternative to contacting your bank, broker or other nominee to coordinate,
or ask questions regarding, the voting of your shares, you may call Alliance Advisors, LLC with any questions at (844) 984-3716, which
is a dedicated line for Bellicum’s stockholders.
/s/ Richard A. Fair
Richard A. Fair
President and Chief Executive Officer
Dated: January 30, 2024
Annex
A
Proxy
Card
PROXY
BELLICUM PHARMACEUTICALS, INC.
THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS
FOR THE 2024 SPECIAL MEETING OF STOCKHOLDERS
TO BE RECONVENED ON FEBRUARY 20, 2024
The stockholder(s) hereby appoint(s) Richard A. Fair and Charles Grass, or any of them, as proxies, each with the power
to appoint his substitute, and hereby authorize(s) them to represent and to vote, as designated on the reverse side of this
ballot, all of the shares of common stock of Bellicum Pharmaceuticals, Inc. that the stockholders are entitled to vote at the
Special Meeting of Stockholders to be reconvened at 8:00 a.m. PT on February 20, 2024 and any additional adjournment
or postponement thereof. The reconvened Special Meeting of Stockholders will be held virtually. In order to attend the
meeting, you must register at http://www.viewproxy.com/BLCM/2024 by 11:59 p.m. ET on February 18, 2024. On the day
of the reconvened Special Meeting of Stockholders, if you have properly registered, you may enter the meeting by clicking
on the link provided and the password you received via email in your registration confirmations. If you previously submitted
a proxy for the special meeting of stockholders as originally convened on January 24, 2024, which proxy has not
subsequently been revoked, we intend to vote those proxies, covering all shares of our capital stock that you are entitled to
vote as of the new record date, at the reconvened special meeting as specifically instructed through your proxy or, if no
direction was given, “FOR” each of the Asset Sale Proposal and the Dissolution Proposal. You may change your vote or
revoke your proxy at any time before it is voted at the special meeting by signing another proxy card with a later date and
returning it to us prior to the special meeting or following the instructions set forth in the Notice of Special Meeting of
Stockholders to be Reconvened on February 20, 2024. Further instructions on how to attend and vote at the Special Meeting
of Stockholders are contained in the Notice of Special Meeting of Stockholders to be Reconvened on February 20, 2024.
UNLESS A CONTRARY DIRECTION IS INDICATED, THIS PROXY WILL BE VOTED FOR PROPOSALS 1 AND 2
SPECIFICALLY DESCRIBED IN THE INFORMATION STATEMENT. IF SPECIFIC INSTRUCTIONS ARE INDICATED,
THIS PROXY WILL BE VOTED IN ACCORDANCE THEREWITH.
(Continued and to be marked, dated, and signed on the other side)
? PLEASE DETACH ALONG PERFORATED LINE AND MAIL IN THE ENVELOPE PROVIDED. •
Important Notice Regarding the Availability of Proxy Materials for theSpecial Meeting of Stockholders to be held on February 20, 2024:
The Information Statement is available at:
http://www.viewproxy.com/BLCM/2024
Please mark your votes like this your votes like this ?
The Board of Directors unanimously recommends a vote “FOR” the approval of the Asset Sale Proposal; and (2) “FOR” the approval of the
Dissolution Proposal.
Proposal 1. To adopt and approve the Asset Purchase Agreement, dated November 21, 2023, as amended on December 8, 2023 (such agreement, as it may be
further amended, modified, or supplemented from time to time, the “Asset Purchase Agreement”), by and among the Company and The University
of Texas M. D. Anderson Cancer Center, an institution of higher education and an agency of the State of Texas (“MDACC”), providing for the sale to
MDACC of certain assets, including all rights to each program of research and development related to (a) CaspaCIDe (inducible caspase-9), the
Rimiducid-inducible safety switch designed to abrogate high-grade adverse events associated with genetically-modified cell therapies, (b) inducible
MyD88/CD40 (iMC), the Rimiducid-inducible activation switch designed to enhance effector cell proliferation and persistence and to resist exhaustion
and inhibitory signals, (c) dual-switch GoCAR-T, incorporating both iMC and a modified rapalog-inducible caspase-9 safety switch, and (d) Rimiducid,
which may be deemed under Delaware law to be a sale of substantially all of our assets and the consummation of the other transactions contemplated
by the Asset Purchase Agreement (the “Asset Sale Proposal” or “Proposal 1”).
DO NOT PRINT IN THIS AREA
(Stockholder Name & Address Data)
Address Change/Comments: (If you noted any Address Changes
and/or Comments above, please mark box.) ?
VIRTUAL CONTROL NUMBER
FOR ?
AGAINST ?
ABSTAIN ?
Proposal 2. To approve, subject to approval of Proposal 1, the liquidation and
dissolution of Bellicum in accordance with Section 275 of the
Delaware General Corporation Law and pursuant to the Plan of
Dissolution (the “Plan of Dissolution”) which, if approved, will
authorize Bellicum to liquidate and dissolve in accordance with
the Plan of Dissolution (the “Dissolution Proposal” or
“Proposal 2”).
FOR ?
AGAINST ?
ABSTAIN ?
Note: To transact such other business as may properly come before the
meeting as determined in the discretion of the proxies.
Please sign exactly as name appears below. When shares are held by joint tenants,
both should sign. When signing as attorney, executor, administrator, trustee, or
guardian, please give full title as such. If a corporation, please sign in full corporate
name by the President or other authorized officer. If a partnership, please sign in
partnership name by authorized person.
Date
Signature
Signature (Joint Owners)
? PLEASE DETACH ALONG PERFORATED LINE AND MAIL IN THE ENVELOPE PROVIDED. •
VIRTUAL CONTROL NUMBER
PROXY VOTING INSTRUCTIONS
Please have your 11-digit control number ready when voting by Internet or Telephone.
INTERNET
Vote Your Proxy on the Internet:
Go to www.AALvote.com/BLCM
Have your proxy card available
when you access the above
website. Follow the prompts to
vote your shares.
TELEPHONE
Vote Your Proxy by Phone:
Call 1-866-804-9616
Use any touch-tone telephone to
vote your proxy. Have your proxy
card available when you call.
Follow the voting instructions to
vote your shares.
MAIL
Vote Your Proxy by Mail:
Mark, sign, and date your proxy
card, then detach it, and return it in
the postage-paid envelope
provided.
v3.24.0.1
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 2 such as Street or Suite number
| Name: |
dei_EntityAddressAddressLine2 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
